GE looks to speed drug discovery with new high capacity system
GE has introduced a new high capacity system designed to improve productivity in the increasingly complex drug discovery process.
GE has introduced a new high capacity system designed to improve productivity in the increasingly complex drug discovery process.
Cellectis has built a switch into a chimeric antigen receptor (CAR) T-cell to provide an efficient way to eliminate the therapy if it becomes a threat to patient safety.
The Jefferson Institute for Bioprocessing is set to launch in spring 2019, in Jefferson University’s new Spring House Innovation Park.